Breaking News

Pfizer to Acquire Global Blood Therapeutics for $5.4B

Gains leading sickle cell disease expertise, portfolio and pipeline with potential combined peak sales of more than $3 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer Inc. and Global Blood Therapeutics, Inc. have entered into a definitive agreement under which Pfizer will acquire GBT, for approximately $5.4 billion. GBT is a biopharmaceutical company dedicated to developing treatments for underserved patient communities, starting with sickle cell disease (SCD). The acquisition adds rare hematology expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical needs in this underserved community.    SCD is a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters